This randomized phase II trial studies how well simvastatin works in reducing pancreatitis
(the inflammation of the pancreas) in patients with pancreatitis that occurs more than once
(recurrent), has worsened quickly (acute), or has persisted or progressed over a long period
of time (chronic). Simvastatin may decrease the inflammation of the pancreas by modulating
the immune response responsible for inflammation. It is not yet known if simvastatin may be
an effective treatment for pancreatitis.